Site-specific conjugation of linker drugs to antibodies and resulting ADCs
AssigneeByondis B.V.
InventorsGerardus Joseph Andreas Ariaans, Rudy Gerardus Elisabeth Coumans
Life of this patent
Estimating the term…
Abstract
The present invention relates to antibody-drug conjugates (ADCs) wherein a linker drug is site-specifically conjugated to an antibody through an engineered cysteine, and their use as a medicament, notably for the treatment of human solid tumours and haematological malignancies, in particular breast cancer, gastric cancer, colorectal cancer, urothelial cancer, ovarian cancer, uterine cancer, lung cancer, mesothelioma, liver cancer, pancreatic cancer, prostate cancer, and leukaemia.
Claims19
An antibody-drug conjugate compound (ADC), comprising an antibody or antigen binding fragment thereof, having an engineered cysteine at light chain position 41 (according to Kabat numbering);
- and
- a linker drug conjugated to said antibody or antigen binding fragment through said engineered cysteine.
Dependencies are inferred from the claim text.